Examinations
Examinations
CYFRA 21-1 is a new tumor marker, also known as a fragment of cytokeratin 19, and is one of the most specific tests for detecting lung, esophageal, and bladder cancers. In bronchial cancer, a positive CYFRA 21-1 test result is 85% higher than that of other markers such as CEA and SCC. We have found that Cyfra 21-1 and CA-15-3 possess higher sensitivity and specificity in distinguishing malignant pleural effusions from benign ones. The combined use of these two markers yields more accurate results. This test is performed using the Fujirebio Diagnostics CYFRA 21-1 enzyme immunoassay. Results obtained with different analytical methods or kits are not interchangeable and cannot be interpreted as definitive evidence of the presence or absence of malignancy. CYFRA 21-1 is used as a tumor marker for screening esophageal, lung, and bladder cancers.
- Biomaterial for the study: venous blood.
- Do not consume any food for 8 hours before the test.
- Stop taking medications 24 hours before the test (with the consent of your attending physician).
In case of lung cancer symptoms:
Cough, shortness of breath, signs of compression due to edema of surrounding structures (hoarseness, difficulty swallowing), and paraneoplastic syndromes (hypercalcemia, cushingoid syndrome, Lambert-Eaton syndrome).
In case of intestinal cancer symptoms:
Iron deficiency anemia, rectal bleeding, abdominal pain, constipation, or diarrhea.
In cases of suspected breast cancer.
When planning treatment for metastatic thyroid cancer.
Causes of Elevated CYFRA 21-1 Levels:
- Non-small cell lung cancer
- Colon adenocarcinoma
- Metastases from breast cancer
- Metastatic adenocarcinoma of the thyroid gland
- Small cell lung cancer
- Interstitial lung disease
- Chronic obstructive pulmonary disease (COPD)
- Tuberculosis
- Peritoneal dialysis and hemodialysis
- Diabetic nephropathy
- Chronic renal failure
- Liver cirrhosis and other hepatobiliary diseases
- Pleuritis
- Pericarditis